In the call, Grade noted that only a small part of Baxter's total turnover is in China. But, “given the size of the rates that have been set between the two countries, these rates are now good for almost half of the total impact,” he said.
The grandstand reported that Baxter is now investigating ways to dampen the financial blow of the rates, including wearing extra inventory, identifying alternative suppliers, alternative shipping routes and “targeted price actions”. Baxter also works with trade organizations to lobby for exemptions.
In general, health care and the medical sector, including hospitals, is brace for price increases and shortages of the rates. The Supply Chain in America is miserably vulnerable, which became painfully clear in the midst of the COVID-19 Pandemie.
Baxter is not only in the announcement of heavy rates. Earlier this week you said Healthcare Technologies Inc. That the rates would cost the company around $ 500 million this year, according to financial services Morningstar. And in April Abbott Laboratories said that according to the stands the rates will cost “a few hundred million dollars”.
